|
The following information was reported to gore: on (b)(6) 2022, the patient underwent an emergency endovascular treatment of a thoracoabdominal aortic aneurysm using gore® excluder® conformable aaa endoprostheses.On (b)(6) 2023, it was confirmed a type iiia endoleak.Reportedly three devices were implanted on (b)(6), but it was not determined which devices are related to the event, type iiia endoleak.A reintervention for adding stent grafts was planned on (b)(6) 2023.There is no detailed information regarding the reintervention.
|
|
Code (b)(4)- a review of the manufacturing records indicated the lot met all pre-release specifications.Code (b)(4) -the device remains implanted and was therefore not available for engineering evaluation by gore.According to the gore® excluder® conformable aaa endoprosthesis instructions for use (ifu), potential adverse events that may occur and/or require intervention include, but are not limited to, endoleaks and reoperation.Since it is unknown which device is directly implicated in this complaint, (b)(4)/sn# (b)(4) and (b)(4)/sn# (b)(4) will also be included on this report.W.L.Gore & associates, inc.(gore) is submitting this report to comply with 21 c.F.R.Part 803, the medical device reporting regulation.This report is based upon information obtained by gore, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Blank fields present on this report include required fields and fields determined to be not applicable.Blank required fields indicate that the information was not provided, was deemed unavailable or was not applicable.This report does not constitute an admission or a conclusion by fda, gore, or its associates that the device, gore or its associates caused or contributed to the event described in the report.In particular, this report does not constitute a legal admission by anyone that the product described in this report has any defects or has malfunctioned, as defined from a legal standpoint.These words are included in the report and are fixed items for selection created by the fda, to categorize the type of event solely for the purpose of reporting pursuant to part 803.This statement should be included with any information or report disclosed to the public under the freedom of information act.
|